INTERVENTION 1:	Intervention	0
Zoledronic Acid 5 mg IV	Intervention	1
zoledronic acid	CHEBI:46557	0-15
Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).	Intervention	2
zoledronic acid	CHEBI:46557	8-23
time	PATO:0000165	64-68
month	UO:0000035	88-93
month	UO:0000035	106-111
month	UO:0000035	116-121
urine	UBERON:0001088	137-142
Inclusion Criteria:	Eligibility	0
Postmenopausal women with Stage I, II or IIIa breast cancer being treated with a non-steroidal Aromatase Inhibitor (AI) .Negative bone scan (no bone metastases).	Eligibility	1
breast cancer	DOID:1612	46-59
inhibitor	CHEBI:35222	105-114
Calculated creatinine clearance > 40 ml/min	Eligibility	2
creatinine clearance	CMO:0000765	11-31
Documented T score of less than or equal to -1.5 on Dual Energy X-ray Absorptiionmetry (DXA) scan at the lumbar spine or femoral neck within 3 months prior to screening.	Eligibility	3
t	CHEBI:36371,BAO:0001260	7-8
t	CHEBI:36371,BAO:0001260	11-12
t	CHEBI:36371,BAO:0001260	27-28
t	CHEBI:36371,BAO:0001260	41-42
t	CHEBI:36371,BAO:0001260	76-77
t	CHEBI:36371,BAO:0001260	83-84
t	CHEBI:36371,BAO:0001260	99-100
t	CHEBI:36371,BAO:0001260	101-102
t	CHEBI:36371,BAO:0001260	136-137
t	CHEBI:36371,BAO:0001260	146-147
t	CHEBI:36371,BAO:0001260	156-157
neck	GO:0044326,UBERON:0000974	129-133
Urine NTx > 50 nano moles(nM)based on second morning void.	Eligibility	4
urine	UBERON:0001088	0-5
second	UO:0000010	38-44
Signed informed consent.	Eligibility	5
Ambulatory patients at least 18 years of age.	Eligibility	6
age	PATO:0000011	41-44
Eastern Cooperative Oncology Group (ECOG)0-2.	Eligibility	7
group	CHEBI:24433	29-34
Ability to comply with trial requirements.	Eligibility	8
Exclusion Criteria:	Eligibility	9
Bone Metastases.	Eligibility	10
Any woman of child bearing potential.	Eligibility	11
Patients with fractures occurring within three months prior to randomization. - Greater than a 2+ protein on urine dipstick without evidence of contamination or bacteriuria (may be repeated one time, at least a day apart).	Eligibility	12
protein	CHEBI:36080,BAO:0000175	98-105
urine	UBERON:0001088	109-114
bacteriuria	HP:0012461,DOID:1412	161-172
time	PATO:0000165	194-198
day	UO:0000033	211-214
Calculated creatinine clearance less than 30 mL/min at screening.	Eligibility	13
creatinine clearance	CMO:0000765	11-31
Serum calcium > 2.75 mmol/L (11.0 mg/dL) or < 2.00 mmol/L (8.0 mg/dL).	Eligibility	14
calcium	CHEBI:22984,BAO:0000874	6-13
Liver Function tests (LFT)> 2.0 x upper limit of normal (ULN).	Eligibility	15
liver	UBERON:0002107	0-5
function	BAO:0003117,BFO:0000034	6-14
x	LABO:0000148	32-33
Serum alkaline phosphatase > 1.5 x ULN. History of hypersensitivity to bisphosphonates.	Eligibility	16
phosphatase	GO:0016791,BAO:0000295	15-26
x	LABO:0000148	33-34
history	BFO:0000182	40-47
hypersensitivity	GO:0002524,DOID:1205	51-67
Evidence of vitamin D deficiency (serum 25-(OH) D of less than 15 ng/ml).	Eligibility	17
vitamin d	CHEBI:27300	12-21
History of uveitis or iritis, except when secondary to trauma, and must have resolved > 2 years prior to entry.	Eligibility	18
history	BFO:0000182	0-7
uveitis	HP:0000554,DOID:13141	11-18
iritis	HP:0001101,DOID:1406	22-28
A history of invasive malignancy of any organ system, treated or untreated, within the past 12 months prior to screening; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, Ductal Carcinoma in-situ (DCIS) that has been surgically removed, and Carcinoma in-situ (CIS) of the uterine cervix that has been surgically removed.	Eligibility	19
history	BFO:0000182	2-9
organ	UBERON:0000062	40-45
squamous cell carcinoma of the skin	HP:0006739	147-182
carcinoma	HP:0030731,DOID:305	161-170
carcinoma	HP:0030731,DOID:305	260-269
carcinoma	HP:0030731,DOID:305	323-332
uterine cervix	UBERON:0000002	354-368
Previous major solid organ transplant recipient or on a transplant waiting list.	Eligibility	20
organ	UBERON:0000062	21-26
Treatment with any investigational drug within 30 days prior to randomization.	Eligibility	21
drug	CHEBI:23888	35-39
History of hyperparathyroidism, hypoparathyroidism, Osteogenesis imperfecta, Paget's disease or any metabolic bone disease other than osteoporosis.	Eligibility	22
history	BFO:0000182	0-7
hyperparathyroidism	HP:0000843,DOID:13543	11-30
hypoparathyroidism	HP:0000829,DOID:11199	32-50
osteogenesis imperfecta	DOID:12347	52-75
disease	DOID:4,OGMS:0000031	85-92
disease	DOID:4,OGMS:0000031	115-122
bone disease	DOID:0080001	110-122
osteoporosis	HP:0000939,DOID:11476	134-146
Any medical condition which would interfere with the action of the study drug or limit life expectancy to less than 6 months.	Eligibility	23
condition	PDRO:0000129	12-21
drug	CHEBI:23888	73-77
Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial.	Eligibility	24
condition	PDRO:0000129	27-36
Prior treatment with IV bisphosphonates within the last 2 years.	Eligibility	25
Previous use of oral bisphosphonates within the past 2 years (unless used for less than 8 weeks*). *NOTE: If used less than 8 weeks, the washout period is 6 months.	Eligibility	26
Treatment with raloxifene, calcitonin, tibolone or hormone replacement therapy. The washout period for these medications is 6 months prior to randomization.	Eligibility	27
raloxifene	CHEBI:8772	15-25
calcitonin	CHEBI:3306	27-37
tibolone	CHEBI:32223	39-47
hormone	CHEBI:24621	51-58
Any treatment with strontium ranelate, samarium, sodium fluoride or parathyroid hormone.	Eligibility	28
sodium fluoride	CHEBI:28741	49-64
hormone	CHEBI:24621	80-87
Use of systemic high dose corticosteroids at an average dose of > 7.5 mg per day of oral prednisone or equivalent for a period of three months or more prior to screening.	Eligibility	29
day	UO:0000033	77-80
prednisone	CHEBI:8382	89-99
Known hypersensitivity to zoledronic acid or other bisphosphonates.	Eligibility	30
hypersensitivity	GO:0002524,DOID:1205	6-22
zoledronic acid	CHEBI:46557	26-41
Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.	Eligibility	31
active	PATO:0002354	8-14
osteonecrosis	DOID:10159	161-174
mouth	UBERON:0000165	216-221
Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).	Eligibility	32
surgery	OAE:0000067	49-56
Outcome Measurement:	Results	0
Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range at 12 Months	Results	1
urine	UBERON:0001088	28-33
range	LABO:0000114	76-81
17 women with early breast cancer receiving adjuvant Aromatase Inhibitor (AI) therapy were treated with a single 5 mg IV dose of zoledronic acid. Urine and serum NTx and serum CTx were measured at baseline and month 12.	Results	2
breast cancer	DOID:1612	20-33
adjuvant	CHEBI:60809	44-52
inhibitor	CHEBI:35222	63-72
zoledronic acid	CHEBI:46557	129-144
urine	UBERON:0001088	146-151
month	UO:0000035	210-215
Time frame: One year	Results	3
time	PATO:0000165	0-4
year	UO:0000036	16-20
Results 1:	Results	4
Arm/Group Title: Zoledronic Acid 5 mg IV	Results	5
zoledronic acid	CHEBI:46557	17-32
Arm/Group Description: Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).	Results	6
zoledronic acid	CHEBI:46557	31-46
time	PATO:0000165	87-91
month	UO:0000035	111-116
month	UO:0000035	129-134
month	UO:0000035	139-144
urine	UBERON:0001088	160-165
Overall Number of Participants Analyzed: 13	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  13	Results	9
Adverse Events 1:	Adverse Events	0
Total: 0/17 (0.00%)	Adverse Events	1
